CNS Drugs

, Volume 14, Issue 1, pp 1–9 | Cite as

Thrombolysis in the Treatment of Acute Ischaemic Stroke

What are the Likely Pharmacoeconomic Consequences?
  • Perttu J. Lindsberg
  • Risto O. Roine
  • Markku Kaste
Leading Article


Stroke kills 4.4 million individuals annually and is the most significant cause of somatic disability. Ultra-acute thrombolysis is the only proven specific medical therapy for stroke, but the pharmacoeconomic consequences of wide application of thrombolytic therapy have not been broadly reported. This review analyses available data on costs incurred by stroke morbidity and estimates how these might be influenced by thrombolytic therapy. These analyses are supported by: (i) estimated lifetime costs of stroke therapy (approximately $US60 000 per patient); (ii) a speculative example of thrombolytic therapy simulated in the setting of a comprehensive urban stroke centre; and (iii) recent data on the efficacy of thrombolysis in reducing disability. It is estimated that only 5% of acute stroke patients are eligible for thrombolysis, which prevents 1 case of long term disability among every 7 patients treated.

It can be argued that the reduction in costs during the first year of medical therapy (e.g. rehabilitation, co-morbidity, nursing) due to successful thrombolysis is cancelled out by increased costs due to the associated investments (increased acute hospitalisations and neuroimaging, drug costs and potential complications). However, successful thrombolysis cuts all lifetime indirect costs (e.g. disability pensions, reduced income and productivity) and direct nonmedical costs (e.g. disability aids, domestic help), and significantly reduces lifetime direct medical costs (e.g. rehabilitation, stroke co-morbidity, nursing). In such a case, these savings are estimated to account for 84% of the total lifetime costs (approximately $US52 200).

In our catchment area of 1 million individuals, the projected total savings in a simulated model of thrombolytic therapy would amount to 15 to 26% of the expenses budgeted for in-hospital therapy of the 800 patients with ischaemic stroke who are treated annually at our centre. Alternatively, the savings due to one successful thrombolysis cancel out the costs for the acute phase management of the number of patients needed to generate this nondisabled stroke survivor. Although these estimates are based on the use of thrombolysis in a well organised stroke care centre in an urban setting, where no substantial investments are necessary before full implementation of thrombolytic therapy can occur, it would seem advantageous to apply thrombolysis as widely as possible to reduce the economic burden of stroke. Since thrombolysis for ischaemic stroke is only well tolerated when administered by experienced clinicians in well established stroke centres, we encourage efforts to disseminate focused training programmes as well as investments in better organised stroke care worldwide3


Acute Stroke Thrombolytic Therapy Alteplase Case Fatality Rate Stroke Centre 


  1. 1.
    Murray CJL, Lopez AD. Mortality by cause for eight regions in the world: Global Burden of Disease Study. Lancet 1997; 349: 1269–76PubMedCrossRefGoogle Scholar
  2. 2.
    Sudlow CLM, Warlow CP. Comparable studies of the incidence of stroke and its pathological subtypes: results from an international collaboration. Stroke 1997; 28: 491–9PubMedCrossRefGoogle Scholar
  3. 3.
    Isard PA, Forbes JF. The cost of stroke to the National Health Service in Scotland. Cerebrovasc Dis 1992; 2: 47–50CrossRefGoogle Scholar
  4. 4.
    The National Institute for Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–7CrossRefGoogle Scholar
  5. 5.
    Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352: 1245–51PubMedCrossRefGoogle Scholar
  6. 6.
    Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017–25PubMedGoogle Scholar
  7. 7.
    Numminen H, Kotila M, Waltimo O, et al. Declining incidence and mortality rates of stroke in Finland from 1972 to 1991. Results of three population-based stroke registers. Stroke 1996; 27: 1487–91Google Scholar
  8. 8.
    Tuomilehto J, Rastenyte D, Sivenius J, et al. Ten-year trends in stroke incidence and mortality in the FINMONICA stroke study. Stroke 1996; 27: 825–32PubMedCrossRefGoogle Scholar
  9. 9.
    Stroke Unit Trialists’ Collaboration. Organised inpatient (stroke unit) care for stroke. The Cochrane Database of Systematic Reviews. Vol. 4. The Cochrane Library, 1999Google Scholar
  10. 10.
    Grond M, Stenzel C, Schmülling S, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998; 29: 1544–9PubMedCrossRefGoogle Scholar
  11. 11.
    Donnan GA. A meta analysis of the three recent large trials of tPA in acute ischemic stroke. Presented at the Third Annual Meeting of Advances in Acute Stroke Management: 1998 Oct 3–5; CreteGoogle Scholar
  12. 12.
    Hankey GJ. Stroke. How large a public health problem, and how can the neurologist help? Arch Neurol 1999; 56: 748–54Google Scholar
  13. 13.
    Kaste M, Fogelholm R, Rissanen A. Economic burden of stroke and the evaluation of new therapies. Public Health 1998; 112: 103–12PubMedGoogle Scholar
  14. 14.
    Terént A, Marké L-Å, Asplund K, et al. Costs of stroke in Sweden. A national perspective. Stroke 1994; 25: 2363–9Google Scholar
  15. 15.
    Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke 1996; 27: 1459–66PubMedCrossRefGoogle Scholar
  16. 16.
    Fagan SC, Morgenstern LB, Petitta A, et al., and the NINDS rt-PA Stroke Study Group. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Stroke 1998; 883–90Google Scholar
  17. 17.
    Kaste M. Worldwide use and reimbursement for thrombolysis. The 5th International Symposium on Thrombolytic Therapy in Acute Ischemic Stroke. National Institutes of Health: 1998 May 1–3; Bethesda (MD)Google Scholar
  18. 18.
    Samsa GP, Reutter RA, Parmigiani G, et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J Clin Epidemiol 1999; 52: 259–71PubMedCrossRefGoogle Scholar
  19. 19.
    Kotila M, Numminen H, Waltimo O, et al. Depression after stroke. Results of the FINNSTROKE study. Stroke 1998; 29: 368–72Google Scholar
  20. 20.
    Matchar DB, Samsa GP, Matthews JR, et al. The stroke prevention policy model (SPPM): linking evidence and clinical decisions. Ann Int Med 1997: 127: 704–11PubMedGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Perttu J. Lindsberg
    • 1
  • Risto O. Roine
    • 1
  • Markku Kaste
    • 1
  1. 1.Department of NeurologyHelsinki University Central HospitalHelsinkiFinland

Personalised recommendations